Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

“Clinical Aspects” Of Wyeth’s Lybrel To Be Publicly Reviewed After “Approvable” Letter

This article was originally published in The Pink Sheet Daily

Executive Summary

Data on bleeding patterns, pregnancy rates and discontinuations for the continuous oral contraceptive will be discussed.

You may also be interested in...



Lybrel To Launch In July Following FDA Approval

Wyeth’s oral contraceptive is the first continuous-use product without a placebo phase or pill-free interval.

Lybrel To Launch In July Following FDA Approval

Wyeth’s oral contraceptive is the first continuous-use product without a placebo phase or pill-free interval.

Wyeth Plans To Launch Lybrel, DVS-233 In 2007 After Resolving Manufacturing Issues

Manufacturing facility concerns likely will derail approval of the oral contraceptive and the antidepressant before the end of the year.

Related Content

Topics

UsernamePublicRestriction

Register

PS064409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel